Version 1
: Received: 4 February 2024 / Approved: 4 February 2024 / Online: 5 February 2024 (06:24:20 CET)
How to cite:
Ferrari, I. V. Examining TNF-Alpha Inhibition Potential: Molecular Docking Study of Pharmaceuticals and Natural Compounds. Preprints2024, 2024020189. https://doi.org/10.20944/preprints202402.0189.v1
Ferrari, I. V. Examining TNF-Alpha Inhibition Potential: Molecular Docking Study of Pharmaceuticals and Natural Compounds. Preprints 2024, 2024020189. https://doi.org/10.20944/preprints202402.0189.v1
Ferrari, I. V. Examining TNF-Alpha Inhibition Potential: Molecular Docking Study of Pharmaceuticals and Natural Compounds. Preprints2024, 2024020189. https://doi.org/10.20944/preprints202402.0189.v1
APA Style
Ferrari, I. V. (2024). Examining TNF-Alpha Inhibition Potential: Molecular Docking Study of Pharmaceuticals and Natural Compounds. Preprints. https://doi.org/10.20944/preprints202402.0189.v1
Chicago/Turabian Style
Ferrari, I. V. 2024 "Examining TNF-Alpha Inhibition Potential: Molecular Docking Study of Pharmaceuticals and Natural Compounds" Preprints. https://doi.org/10.20944/preprints202402.0189.v1
Abstract
Inflammation is a vital aspect of the body's immune response, appearing either as an acute reaction that swiftly develops (e.g., after injury or during an infection) or as a chronic condition that persists over a prolonged period, often linked with autoimmune disorders or cancer. This study introduces potential TNF-alpha inhibitors investigated by Molecular Docking investigation. They are Dactolisib with a binding energy of -10.1 kcal/mol, Nilotinib with -9.6 kcal/mol, Eltrombopag with -9.7 kcal/mol, Radotinib with -9.6 kcal/mol, and Nilotinib again with -9.7 kcal/mol. Additionally, Hypericin exhibited a notable binding energy of -9.9 kcal/mol, suggesting its potential as a natural TNF-alpha inhibitor. While these computational results are preliminary, they provide a foundation for further biological studies to confirm their efficacy. The significance of these findings extends to the scientific community, offering potential applications in the field of inflammatory diseases.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
